Heavy Metal Overload in the walls of coronary arteries seems to decrease levels of nitric oxide, a compound known as “Endothelial Relaxing Factor,” and without this substance normal blood flow is impeded therefore increasing the risk of vascular blockages. Heavy Metal Overload in the adrenal glands reduce the production of hormones, which cause early aging, stress, decreased sex drive and aggravation of menopausal symptoms. Heavy Metal Overload can lead to unresponsiveness of diabetics to their medications. Heavy Metal Overload can lead to neurological diseases such as depression and loss of thinking power. It can also aggravate conditions such as osteoporosis and hypothyroidism. For obviously so many reasons, removing toxic metals from the body safely has been a concern of physicians for many years.

It Improves blood flow without surgery

Atherosclerosis is the narrowing and stiffening of arteries due to the accumulation of pathologic calcium and plaque — is a primary cause of diminished circulation and oxygen to our cells. EDTA chelation therapy is a cost-effective method for avoiding surgery, enhancing the health of the arteries, removing pathologic calcium, improving elasticity, and thus improving circulation.

EDTA Chelation involves the administration of a synthetic amino acid called EDTA (ethylene diamine tetra-acetic acid), it binds to heavy metals such as lead, iron and cadmium that can cause free-radical damage and calcium deposits in the arteries, and carries them harmlessly out of the body through the urine and fecal matter.

This treatment reduces toxic metal-induced free radicals, which cause the development of arteriosclerosis and many other degenerative diseases of aging. The body’s regulation of calcium and cholesterol is improved by normalizing the internal chemistry of cells.  This gives the body time to heal and to restore blood flow through the blood vessels.

EDTA Chelation brings these benefits to every blood vessel in the body, from the largest arteries to the tiniest capillaries, most of which are far too small or deep within the brain and other vital organs for surgical treatment.  In many cases, the smallest blood vessels are the most severely diseased.  The benefits of chelation occur from the top of the head to the bottom of the feet, not just in blocked segments of a few large arteries.

When a vessel thats going to your brain suffers complete blockage, cerebral thrombosis or a stroke is usually the result. The amount of saturated fats, and cholesterol that exists in your bloodstream have a direct relationship to CAD (coronary artery disease) and arterial blockage which deliver blood to the heart.

The main cause for stroke and heart attacks is atherosclerosis. There’s a inner lining of your blood vessels, it’s called the endothelium. This endothelium is extremely important, it’s critical that it does not stop functioning. It produces the very potent and important vessel dilator known as N.O, or Nitric Oxide as well as prostacyclin, which acts to slow the blood clotting while also helping to keep the arteries dilated. And believe it or not, it also produces a third crucial blood product known as heparin. Heparin stops clots from forming. 

The endothelium layer is a storage site for heavy metals, and when too many heavy metals are deposited in the endothelium, it’s unable to produce the vital substances needed for healthy blood flow and cardiovascular health. These are the N.O., heparin. and prostacyclin. 

When the toxic metals are removed the circulation of oxygen and nutrients starts moving, and improvement throughout the whole system begins. 

In the past, the theory was that EDTA was a “biological rotor rooter” for sticky solid plaque, and had a unique mechanism with harmful solids converting into a watery liquid, then pulled away and removed as a normal and natural process by body functions – and this is even believed by some people today. But with the discovery of Nitric Oxide (N.O.) being produced in increased amounts after EDTA chelation, and along with the buildup plaque being eliminated by regular body functions of metabolism. So the body achieves a new levels of health on it’s own, after the metals are removed, and reaches new levels of homeostasis – it’s this that seems to be what is really happening giving us a clearer explanation of the incredible benefits of EDTA chelation. And why EDTA stops and blocks, the calcium channels with arterial walls which causes arterial vasodilation. 

The book that changed everything 

Dr Valentin Fuster MD, published a book in 1999 entitled The Vulnerable Atherosclerotic Plaque. Now this was at the time he was the actual President of The American Heart Association, plus being the Chairman of the Cardiology Department at the Mount Sinai School of Medicine in NYC.

Showing how heart attacks are not occurring in the areas of the most plaque buildup, located near the hardened deposits of large cholesterol, and are instead being triggered in the new fresh and most “vulnerable” plaque. This is where the plaque gets infected with specific germs like the Epstein Barr Virus, Cytomegalovirus and the Herpes Virus, plus several other germs that we get infected with. Now the process of proving and studying these germs being more infectious and abundant when sufficient amounts of N.O. is not produced – is now underway.

Both a very strong anti-oxidant, and powerful vasodilator, N.O. production is reduced when the endothelium suffers damage – vasodilation is reduced, and oppositely, vascular constriction starts. As a direct result of toxic metal insult, the reduction in N.O. production starts restricting blood flow, increasing blood pressure, and the vascular lumen reduces in size – in other words, your risk for heart attack and stroke has increased. What is extremely vital, it seems, is that the secretion and production of N.O. must not be decreased, or the imbalance in function will ultimately cause hypertension – the quiet killer.

Disturbing vascular homeostasis locally, most likely leads to platelet deposition, and many elements start unleashing to cause aggregation which together leads to smooth muscle proliferation. Fibrosis, thrombus formation, and atherosclerosis might be the result. When the metabolic imbalance is first started in the endothelial level, the place where damages trigger an inflammatory response, is first connection in-between coagulation and inflammation. 

The endothelium is assaulted by toxic metals

Now, the arterial wall has built up a small piece of the “Bad” type of cholesterol, or LDL, and it’s starting to oxidize. One of the main triggers that sets off a reaction of events is oxidized LDL, the endothelium starts expressing and unique molecule 

So in the meantime, a little bit of the “Bad” cholesterol (LDL) which has been stockpiled on the arterial walls 

Meanwhile, a small amount of LDL (“Bad”) cholesterol that has built up in the artery wall becomes oxidized. Oxidized LDL is one of the triggers that set off a chain reaction. It causes the endothelium to express a special kind of molecule “glue” called ELAMS (endothelial-leukocyte adhesion molecules). These molecules, which happen to be floating by in the bloodstream causes certain kinds of white blood cells (monocytes and T lymphocytes) to stick to the endothelium. At this point in time, the inflammatory response is still well under control and normal, whether it is in the artery or in the tissue.

Beyond this point, the healing process goes off track. The white blood cells will start to move between and below the endothelium and cause damage in two major ways. Firstly, they will cause some of the muscles cells in the artery walls to grow and secondly, they incorporate particles into the artery wall, consuming the oxidized LDL particles. What results from here is a fatty streak that becomes a fibrous plaque. Toxic heavy metals are ever ready to attack the endothelium. The endothelium, in an attempt to heal itself, launches an inflammatory response to get rid of the unwanted guests.

This intricate process begins in the tissue under the endothelium. Due to inflammatory reactions, the endothelium’s structure becomes permeable to lipoproteins, particularly low-density lipoproteins (LDL) and macrophages. These particles will enter into the site of injury, accumulate cholesterol as cholesterylester and develop into foam cells. A raised LDL cholesterol and related cholesterol carrier called lipoprotein (a) concentration is recognized by many as a major risk factor for heart disease as it appears to be the donor of cholesterol deposited in the atherosclerotic plaque. Being adhesive, the cells will attract other substances, resulting in a continuous deposition of unwanted conglomerate which we call fatty streak. The latter consists of lipids (fats), complex carbohydrates, blood, blood products, fibrous tissue, oxidized ascorbates and calcium deposits. As the fatty streak becomes increasingly larger, this resulting fibrosis forms an “endothelial tumor” or a plaque. The process of plaque formation is called atherosclerosis. Atherosclerosis blocks the blood’s pathway and narrows the arteries over time. This affords a possible explanation for the beneficial effects of chelation. In addition, EDTA blocks the slow calcium currents in the arterial wall, resulting in arterial vasodilation.

“The Ca-sodium form is able to bond (chelate) effectively because it does not lower the blood pH to a level that would prohibit the bonding action. The Ca added to the salt is important in this MOA (mode of administration) as it buffers the acidic quality of the active ingredient keeping the suppository from being abrasive to the mucous membrane of the rectum area. Ca-disodium EDTA has both a scientific justification for therapeutic effectiveness as well as a clinical history of effectiveness.” Dr. Bruce Halstead MD, Scientific Advisor to Detoxamin

See Ca-EDTA affinity chart here


  1. Lustberg, Mark and Silbergeld, Ellen. Blood lead levels and mortality. Arch Intern Med, 2002, 162: 2443-2449.
  2. “Questions & Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Artery Disease” 2002 www.nccam,nih,gov/news/2002/chelation/q-and-a.htm
  3. Pinkle, J.L., Brody, D.J., Gunter, E.W., et al. The decline in blood lead levels in the United States: the National Health and Nutrition Examination Surveys (NHANES). JAMA, 1994, 272: 284-291
  4. Cranton EM, Frackelton JP “Free Radical Pathology in Age-Associated Diseases: Treatment with EDTA Chelation, Nutrition and Antioxidants” Journal of Advancement in Medicine 1989 Spring/Summer;2(1-2)
  5. Cranton E, ed. A Textbook on EDTA Chelation Therapy, Special Issue of Journal of Advancement in Medicine, Volume 2, Numbers 1/2, Human Sciences Press, Inc, 233 Spring Street, New York, New York 10013-1578, p. 155, Spring/Summer 1989. J Adv Med 1989;2:1-416, 1989
  6. Blumer W, Reich T. Leaded gasoline – a cause of cancer. Environ Internat. 1980;3:465-471.
  7. Tandon SK, Surendra S, Vinod KJ. Efficacy of combined chelation in lead intoxication. American Chemical Society. 1994;7(5).
  8. Cranton E and Brecher A. Bypassing Bypass – The New Technique of Chelation Therapy. Medex Publishers. 1990.
  9. Olszewer E and Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hyp27(1): 41-9. 1988.
  10. Hancke C and Flytlie K. Manipulation with EDTA. Ugeskar Laeger154(32): 2213-5. 1992.
  11. Rudolph CJ, McDonagh EW. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation on carotid circulation: case report. J Advancement in Med. 3(1): 5-12. 1990.
  12. McDonagh EW, Rudolph CJ and Cheraskin E. An oculocerebrovasculometric analysis of the improvement in arterial stenosis following EDTA chelation therapy. J Hol Med4(1): 21-3. 1982.
  13. McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus multivitamin/trace mineral supplementation upon vascular dynamics (ankle/brachial systolic blood pressure). J Hol Med7(1): 16-22. 1985.
  14. Guldager B, et al. EDTA treatment of intermittent claudication – a double-blind, placebo controlled study. J Int Med. 231(3): 261-7. 1992.
  15. EDTA chelation: a rebuttal. J Advancement in Med5(1): 3-5. 1992.
  16. Cranton EM and Frackelton JP. Negative Danish study of EDTA chelation biased. Townsend Letter for Doctors. 604-5. July 1992.
  17. Rudolph CJ, McDonagh EW and Barber RK. A Nonsurgical Approach to Obstructive Carotid Stenosis Using EDTA Chelation. Journal of Advancement in Medicine4(3): 157-67. 1991.